Ionis (NASDAQ: IONS) HR chief sells 6,193 shares in 10b5-1 plan

Rhea-AI Filing Summary

Ionis Pharmaceuticals executive Shannon L. Devers, EVP and Chief Human Resources Officer, sold 6,193 shares of Common Stock in an open-market transaction at a weighted average price of $74.0535 per share on April 2, 2026. The sale was made pursuant to a Rule 10b5-1 Trading Plan adopted on November 24, 2025. After this transaction, Devers directly holds 16,348 shares of Ionis Pharmaceuticals common stock.

Insider Trade Summary 10b5-1

Net Seller: 6,193 shares ($458,613)

Net Sell 1 txn

Insider Devers Shannon L.

Role EVP, Chief Human Resources Ofc

Sold 6,193 shs ($459K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,193	$74.0535	$459K

Holdings After Transaction: Common Stock — 16,348 shares (Direct)

Footnotes (1)

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.62 to $74.2450 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Key Figures

Shares sold: 6,193 shares Weighted average sale price: $74.0535 per share Post-transaction holdings: 16,348 shares +1 more

4 metrics

Shares sold 6,193 shares Open-market sale of common stock on April 2, 2026

Weighted average sale price $74.0535 per share Common stock sale price, multiple trades in stated range

Post-transaction holdings 16,348 shares Common stock directly held after reported sale

Price range of transactions $73.62–$74.2450 per share Range for individual trades included in weighted average

Key Terms

Rule 10b5-1 Trading Plan, weighted average price, open-market sale, Common Stock

4 terms

Rule 10b5-1 Trading Plan financial

"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Devers Shannon L.

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CALIFORNIA 92010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Human Resources Ofc

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/02/2026		S		6,193(1)	D	$74.0535(2)	16,348	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.62 to $74.2450 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

	By: Patrick R. O'Neil, attorney-in-fact For: Shannon Devers	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Ionis (IONS) executive Shannon Devers report in this Form 4?

Shannon L. Devers reported selling 6,193 Ionis shares. The EVP and Chief Human Resources Officer executed an open-market sale of common stock at a weighted average price of $74.0535 per share and now directly holds 16,348 shares.

How many Ionis (IONS) shares did Shannon Devers sell and at what price?

Devers sold 6,193 Ionis common shares at $74.0535 each. The filing notes this is a weighted average price, with multiple trades executed in a price range between $73.62 and $74.2450 on the transaction date.

Does the Ionis (IONS) Form 4 for Shannon Devers involve a 10b5-1 plan?

Yes. The sale was made under a Rule 10b5-1 Trading Plan. The filing states the shares were sold pursuant to a plan adopted by Shannon L. Devers on November 24, 2025, indicating the transactions were pre-arranged in advance.

How many Ionis (IONS) shares does Shannon Devers hold after the reported sale?

Devers directly holds 16,348 Ionis shares after the sale. The Form 4 shows this post-transaction balance of common stock, giving context for the size of the 6,193-share open-market disposition relative to her remaining position.

What price range did Ionis (IONS) shares trade at for this Devers sale?

The trades occurred between $73.62 and $74.2450 per share. The Form 4 explains the reported $74.0535 price is a weighted average, with multiple individual transactions executed within that specified range on the sale date.